Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Abramson Cancer Center at Penn Medicine1 site in 1 country208 target enrollmentNovember 3, 2022

ConditionsCancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Enrollment: 208
Locations: 1
Primary Endpoint: Quality of Life - McGill Quality of Life Questionnaire
Status: Active, not recruiting
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.

Registry

clinicaltrials.gov

Start Date

November 3, 2022

End Date

August 1, 2026

Last Updated

5 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Abramson Cancer Center at Penn Medicine

Responsible Party

Principal Investigator

Scott Halpern

Associate Professor of Medicine

University of Pennsylvania

Eligibility Criteria

Inclusion Criteria

•Be a new patient at an outpatient palliative care clinic
•Resident of Pennsylvania
•Over 18 years of age

Exclusion Criteria

•Prior use of certain symptom focused therapies
•Currently pregnant

Outcomes

Primary Outcomes

Quality of Life - McGill Quality of Life Questionnaire

Time Frame: Baseline - 16 weeks

Quality of life will be measured through the McGill Quality of Life Questionnaire Revised (MQOL-R). The questionnaire is 15 questions assessing overall and specific areas of quality of life.

Secondary Outcomes

Acceptability of Accessing Additional Resources for Symptom Management(Baseline - 16 weeks)
Medication Use(Baseline - 16 weeks)
Hospital-Free Days(Baseline - 16 weeks)
Feasibility of Accessing Additional Resources for Symptom Management(Baseline - 16 weeks)
Symptom Severity(Baseline - 16 weeks)
Mortality(Baseline - 16 weeks)